Inogen Announces Participation in the Stifel 2020 Virtual Healthcare Conference

GOLETA, Calif.–(BUSINESS WIRE)–Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the Stifel 2020 Virtual Healthcare Conference.

Inogen’s President and CEO, Scott Wilkinson, and CFO, Alison Bauerlein, are scheduled to present on Tuesday, November 17th, 2020 at 4:00 p.m. EST at the Stifel 2020 Virtual Healthcare Conference. Interested parties can access the live audio webcast from the News / Events section of the Investor Relations page on the Inogen website at www.inogen.com. A webcast replay will be available approximately one hour after the conclusion of the live presentation and will remain available for 90 days.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

Inogen is a medical technology company offering innovative respiratory products for use in the homecare setting. Inogen primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

Contacts

Investor Relations Contact:
Matthew Pigeon

mpigeon@inogen.net

Media Contact:
Byron Myers

805-562-0503

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

4 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

7 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

7 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

7 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

7 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

7 hours ago